KRYSP-R is developing a portable CRISPR-based diagnostic platform combined with lateral flow assays (LFAs) for rapid, sensitive, and cost-effective on-field detection of genetic modifications in plant GMOs. The technology aims to deliver results within 30-40 minutes, enabling real-time monitoring, regulatory compliance, and contamination prevention in agricultural settings.
KRYSP-R is developing a CRISPR-based rapid on-field detection platform designed to transform how genetically modified organisms (GMOs) are characterized in agricultural environments. Traditional GMO detection methods, such as PCR and sequencing, are often time-consuming, expensive, and require specialized laboratory equipment and trained personnel. This innovation addresses those limitations by combining CRISPR's precision nucleic acid recognition with lateral flow assay (LFA) technology to create a portable, user-friendly diagnostic tool.
The platform targets both point mutations and large gene insertions in plant GMOs, delivering highly sensitive and specific detection suitable for precision agriculture, regulatory compliance, and contamination prevention. By enabling real-time, on-site decision-making, the technology helps farmers, seed producers, and regulatory agencies reduce costs and accelerate workflows.
The technology is currently at an early-to-mid development stage. KRYSP-R has validated a similar CRISPR-based point-of-care detection system for plant pathogens, demonstrating fluorescence-based detection at varying limits of detection (LOD) through in-silico probe design and in-vitro cleavage efficiency assessments. The next milestone is the development of an all-in-one lateral flow strip-based detection system for plant pathogens, which will serve as a foundation for extending the platform to GMO detection. Future validation plans include designing GMO-specific CRISPR probes, building a portable integrated device, benchmarking against PCR and sequencing for sensitivity and specificity, optimizing to minimize false positives and negatives, and conducting field trials across diverse growing conditions and GMO varieties.
KRYSP-R is a biotechnology company founded in 2021 that specializes in CRISPR-based genome engineering services. The firm provides a range of solutions, including the generation of gene knock-in and knock-out cell lines for mammalian research, genome editing in plant cell lines to improve agricultural yields, and the study of microorganisms to identify potential drug targets. Their technical offerings also include pre-validated CRISPR reagents and plasmids. Operating with facilities in both the United States and India, the company utilizes a state-of-the-art laboratory environment, including a strategic presence at the Centre for Cell and Molecular Platforms (C-CAMP) in Bangalore, to support scientific research and development.
These services are designed to assist researchers and pharmaceutical developers in solving complex genome engineering challenges by providing fast, accurate, and affordable tools. By offering tailor-made, client-specific genome editing solutions, KRYSP-R aims to make advanced CRISPR technology more accessible to laboratories globally. The company serves the biotechnology, pharmaceutical, and healthcare sectors, addressing critical needs in disease modeling, therapeutic research, and agricultural innovation. Their approach leverages deep expertise in genetics to help partners navigate scientific bottlenecks, improve research productivity, and accelerate the development of new treatments and products."},field_source_urls:[{field: